|
Administration
Should be taken with food.
|
|
Contraindications
Hypophosphataemia, bowel obstruction.
|
|
Special Precautions
Patient with dysphagia, swallowing disorders, active inflammatory bowel disease, severe gastrointestinal motility disorders (e.g. untreated or severe gastroparesis, gastric contents retention, abnormal or irregular bowel motion, severe constipation), major gastrointestinal tract surgery; hypothyroidism. Pregnancy and lactation. < I>Monitoring Parameters
|
|
Adverse Reactions
Significant: Serious gastrointestinal tract inflammatory disorders (e.g. haemorrhage, obstruction, perforation, ulceration, necrosis, colitis, colonic or caecal mass), peritonitis, metabolic acidosis; dysphagia and oesophageal tablet retention (tab).
Gastrointestinal disorders: Nausea, vomiting, abdominal pain, constipation, dyspepsia, diarrhoea, flatulence.
Skin and subcutaneous tissue disorders: Rash, pruritus.
|
|
Drug Interactions
May decrease the serum concentration of ciclosporin, mycophenolate mofetil, tacrolimus, and levothyroxine. Decreases the bioavailability of ciprofloxacin. May increase phosphate levels with PPIs. May reduce the absorption of vitamin A, D, E, K, and folic acid.
|
|
ATC Classification
V03AE02 - sevelamer ; Belongs to the class of drugs used in the treatment of hyperkalemia and hyperphosphatemia.
|
Sign Out
